Look up one drug

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Pamidronate Disodium for Injection · DIN 02246597 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2019-08-30 Health Canada: Marketed since 2015-07-07 · brand PAMIDRONATE DISODIUM FOR INJECTION · ATC M05BA03 PAMIDRONIC ACID · form Solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 3 MG/ML · company Fresenius kabi canada ltd · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02246597). DIN 02246597: Pamidronate Disodium for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000562; group id 946; item number 2249; lccId None; manufacturer id FKC Source form: Inj Sol-10mL Vial; strength: 3mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $86.7800; ministry $86.7800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246597 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70784

Interchangeable products

Aredia · DIN 02059762 · not recorded Pamidronate Disodium Omega · DIN 02249669 · $86.7800

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246597

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Pamidronate Disodium Omega · DIN 02249677 Manufacturer: Omega Laboratories Ltd.; listing date 2011-12-15 Health Canada: Marketed since 2006-05-24 · brand PAMIDRONATE DISODIUM OMEGA 6 MG/ML · ATC M05BA03 PAMIDRONIC ACID · form Solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 6 MG/ML · company Omega laboratories limited · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02249677). DIN 02249677: Pamidronate Disodium Omega Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000563; group id 946; item number 2250; lccId None; manufacturer id OMG Source form: Inj Sol-10mL Vial; strength: 6mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $176.7000; ministry $176.7000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02249677 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73448

Interchangeable products

Aredia · DIN 02059770 · not recorded Pamidronate Disodium for Injection · DIN 02246598 · $176.7000

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02249677

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Pamidronate Disodium for Injection · DIN 02246598 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2019-08-30 Health Canada: Marketed since 2015-07-07 · brand PAMIDRONATE DISODIUM FOR INJECTION · ATC M05BA03 PAMIDRONIC ACID · form Solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 6 MG/ML · company Fresenius kabi canada ltd · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02246598). DIN 02246598: Pamidronate Disodium for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000563; group id 946; item number 2250; lccId None; manufacturer id FKC Source form: Inj Sol-10mL Vial; strength: 6mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $176.7000; ministry $176.7000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246598 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70785

Interchangeable products

Aredia · DIN 02059770 · not recorded Pamidronate Disodium Omega · DIN 02249677 · $176.7000

Shortage status: resolved shortage (ended 2023-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246598

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Pamidronate Disodium Omega · DIN 02249685 Manufacturer: Omega Laboratories Ltd.; listing date 2011-12-15 Health Canada: Marketed since 2005-07-27 · brand PAMIDRONATE DISODIUM OMEGA 9 MG/ML · ATC M05BA03 PAMIDRONIC ACID · form Solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 9 MG/ML · company Omega laboratories limited · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02249685). DIN 02249685: Pamidronate Disodium Omega Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000564; group id 946; item number 2251; lccId None; manufacturer id OMG Source form: Inj Sol-10mL Vial; strength: 9mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $260.3300; ministry $260.3300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02249685 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73449

Interchangeable products

Aredia · DIN 02059789 · not recorded Pamidronate Disodium for Injection · DIN 02246599 · $260.3300

Shortage status: resolved shortage (ended 2025-10-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02249685

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Pamidronate Brand(s): Many Generics DOSAGE FORM/ STRENGTH: 3 mg/mL, 6 mg/mL, 9 mg/mL For the treatment of tumor-induced/malignancy-related hypercalcemia in a palliative care patient. Standard Approval Duration: 12 months 474 High Dose Opioids Effective January 31, 2017, meperidine 50mg tabs and the higher strengths of long-acting opioids including: morphine SR 200mg tabs; hydromorphone CR 24mg and 30 mg caps and fentanyl 75mcg/hr and 100mcg/hr patches were delisted from the ODB Formulary. Access to the higher strengths of long-acting opioids is currently maintained for patients requiring palliative care through the ODB program’s: 1. Palliative Care Facilitated Access (PCFA) mechanism, for prescribers (physicians or nurse practitioners) who are registered PCFA prescribers with their professional associations; AND 2. Exceptional Access Program (EAP) Telephone Request Service (TRS) for physicians who are not PCFA prescribers, according to specific criteria. i) Use of the high-strength opioid must be for a patient considered to have a progressive life-limiting illness requiring palliative care. ii) The use of the high-strength opioid can be for pain or for symptom management. iii) Prescriber must have a consult from a PCFA-registered prescriber with OMA; CPSO of the PCFA-registered prescriber or NPAO or RNAO; license numbers must be provided. Standard Approval Duration: 12 months Renewals are considered with same criteria as above. A new consult from a PCFA- registered prescriber must be provided for each renewal. Post-transplant Drugs EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 316, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Pamidronate Disodium for Injection · DIN 02246599 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2019-08-30 Health Canada: Marketed since 2015-07-09 · brand PAMIDRONATE DISODIUM FOR INJECTION · ATC M05BA03 PAMIDRONIC ACID · form Solution · route Intravenous · ingredients PAMIDRONATE DISODIUM 9 MG/ML · company Fresenius kabi canada ltd · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02246599). DIN 02246599: Pamidronate Disodium for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000564; group id 946; item number 2251; lccId None; manufacturer id FKC Source form: Inj Sol-10mL Vial; strength: 9mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $260.3300; ministry $260.3300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246599 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70786

Interchangeable products

Aredia · DIN 02059789 · not recorded Pamidronate Disodium Omega · DIN 02249685 · $260.3300

Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246599

Shortage record checked 2026-09-13T08:10:21.292534+00:00